Clinical Trial Update: SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial exploring SGLT-2 inhibitors, metabolomics, and cardiovascular/kidney outcomes in Type 2 Diabetes Mellitus; the study status is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Snippet

Sponsor: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED